文献速递血液透析通路

上臂动静脉移植物在血液透析通路中优于前臂移植物

Upper Arm Arteriovenous Grafts are Superior over Forearm Arteriovenous Grafts in Upper Extremity Dialysis Access.
PubMed 文献 · Ann Vasc Surg · 2020-07-29

基于血管质量倡议(VQI)2010–2018年前瞻性收集的真实世界数据,纳入1160例前臂和509例上臂肱动脉动静脉移植物(AVG)患者,比较12个月通畅率及6个月并发症。上臂AVG的12个月一期和二期通畅率均显著高于前臂AVG,伤口感染、窃血综合征和手臂肿胀无差异。

要点

  • 上臂肱动脉AVG的12个月一期和二期通畅率均显著优于前臂AVG
  • 前臂AVG的一期和二期通畅丧失风险在多变量分析中显著升高
  • 6个月伤口感染、窃血综合征和手臂肿胀在两组间无显著差异

核心结论

  • 在上臂肱动脉AVG与前臂AVG的比较中,上臂AVG的一期和二期通畅率更优。

研究设计与样本

  • 基于血管质量倡议(VQI)数据集(2010–2018)的观察性研究。
  • 共识别2063例上肢AVG患者,排除腋动脉至腋动脉上臂AVG 394例后纳入分析。
  • 研究队列包括1160例前臂AVG和509例上臂肱动脉AVG。
  • 主要结局为12个月一期和二期通畅率,其他结局为6个月伤口感染、窃血综合征和手臂肿胀。
  • 采用Kaplan-Meier分析和对数秩检验评估通畅丧失,Cox比例风险模型评估校正关联。

主要发现

  • 前臂AVG患者更常见BMI>30(45% vs 38%,P=0.013)。
  • 前臂AVG患者更常见无既往通路史(73% vs 63%,P<0.001)。
  • 前臂AVG患者更常接受局部区域麻醉(56% vs 43%,P<0.001)。
  • 前臂AVG的12个月一期通畅率显著低于上臂AVG(51.5% vs 62.9%,P<0.001)。
  • 前臂AVG的12个月二期通畅率显著低于上臂AVG(76.4% vs 89.1%,P<0.001)。

关键数值与推荐

  • 前臂AVG 12个月一期通畅丧失校正风险比(aHR)1.66,95%CI 1.33–2.01,P<0.001。
  • 前臂AVG 12个月二期通畅丧失校正风险比(aHR)2.71,95%CI 1.84–3.98,P<0.001。
  • 6个月伤口感染、窃血综合征和手臂肿胀在前臂AVG与上臂AVG之间相似。

临床怎么用

  • 在制定上肢透析通路计划时,可考虑上臂肱动脉AVG在12个月通畅率方面的优势。
  • 前臂AVG与上臂AVG在6个月伤口感染、窃血综合征和手臂肿胀方面表现相似。
  • 选择前臂或上臂AVG位置时需综合患者特征与通畅率获益进行个体化决策。

局限性

  • 本研究为基于VQI数据集的观察性研究,可能存在混杂和选择偏倚。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In this study, we compared the outcomes of forearm arteriovenous grafts (AVGs) and upper arm AVGs in a large, prospectively collected data set, which represents real-world experience with upper extremity prosthetic dialysis access, to determine if there are clinically significant differences in the upper arm and forearm positions. METHODS: We identified 2,063 patients who received upper extremity AVGs within the Vascular Quality Initiative data set (2010-2018). Axillary to axillary upper arm AVGs were excluded (n = 394) from the analysis. The main outcome measures were primary and secondary patency rates at 12 months. Other outcomes were 6-month wound infection, steal syndrome, and arm swelling. The log-rank test was used to evaluate patency loss using a Kaplan-Meier analysis. Cox proportional hazards models were used to examine adjusted association between locations (forearm and upper arm) and outcomes. RESULTS: There were 1,160 forearm AVGs and 509 upper arm brachial artery AVGs in the study cohort. Patients with forearm AVGs were more likely to have a body mass index > 30 (45% vs. 38%, P = 0.013), no history of previous access (73% vs. 63%, P < 0.001), and underwent local-regional anesthesia (56% vs. 43%, P < 0.001). The 12-month primary patency (51.5% vs. 62.9%, P < 0.001) and secondary patency (76.4% vs. 89.1%, P < 0.001) were significantly lower for forearm AVGs. Wound infection, steal syndrome, and arm swelling were similar between forearm AVGs and upper arm AVGs at the 6-month follow-up. In multivariable analysis, the primary patency loss (adjusted hazard ratio (aHR) 1.66, 95% confidence interval (CI) 1.33-2.01, P < 0.001) and 12-month secondary patency loss (aHR 2.71, 95% CI 1.84-3.98, P < 0.001) were significantly higher for forearm AVGs at 12 months. CONCLUSIONS: From this observational study of the Vascular Quality Initiative data set, the primary and secondary patency rates were superior for upper arm brachial artery AVGs compared with forearm AVGs.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Fadia R, Berman SS, Chong CC, et al. Upper Arm Arteriovenous Grafts are Superior over Forearm Arteriovenous Grafts in Upper Extremity Dialysis Access. Ann Vasc Surg. 2020. PMID: 32736028. doi:10.1016/j.avsg.2020.07.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。